Compare KraneShares CSI China Internet ETF (KWEB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs State Street SPDR S&P Biotech ETF — how do they compare? KraneShares CSI China Internet ETF trades at $27.52, while State Street SPDR S&P Biotech ETF trades at $158.71. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| KWEB | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $42.94 | $164.28 |
52-Week Low | $23.63 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $27.55 after a 5.39% decline amid broader pressure on Chinese stocks. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $28. Recent institutional buying and strong Chinese export data provide fundamental support, though regulatory and geopolitical risks persist for China-focused internet companies.
The ETF offers exposure to China's internet sector at depressed valuations, with AI and export growth as catalysts. However, investors face significant regulatory uncertainty and US-China tensions. Wall Street sentiment is mixed, balancing growth potential against structural risks in the Chinese market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
